drugset / Trial / NCT00738751
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase 1
Completed
44 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc. · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of the study is to: * Determine the safety and tolerability of erlotinib and LBH589B. * Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
Timeline
- Start
- 2008-11
- Primary completion
- 2013-08
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |
| Subject | Panobinostat | Small molecule | 30 mg | Oral |
| Subject | Panobinostat | Small molecule | 40 mg | Oral |